Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Plus Therapeutics ( (PSTV) ) is now available.
On October 16, 2025, Plus Therapeutics, Inc. entered into a lease agreement with LG 1 Property Owner LP for approximately 11,370 rentable square feet of space at 6420 Levit Green Boulevard, Houston, Texas. The lease, commencing on or about November 1, 2026, includes a monthly base rent of $58,745, with an annual increase of approximately 3%, and has an initial term of 120 months.
The most recent analyst rating on (PSTV) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, with consistent losses and negative equity posing significant risks. While technical analysis shows some positive trends, the negative valuation metrics further weigh down the score.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 22,887,200
Technical Sentiment Signal: Sell
Current Market Cap: $57.5M
See more insights into PSTV stock on TipRanks’ Stock Analysis page.